Nxera Pharma

Focus: Nxera Pharma is a Japanese-based umbrella pharmaceutical company focused on neurology and oncology with a publicly traded status. The company operates as a holding structure overseeing drug development across multiple therapeutic areas.

Neurology Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Nxera Pharma

AI assessmentNot Hiring

No open roles listed right now. Follow Nxera Pharma to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

HTL0009936

Alzheimer's Disease

PHASE_1

Clinical Trials (1)

NCT02546310Phase 1 Study Investigating Effects of HTL0009936 on Cognition and BOLD fMRI Signals in Healthy Elderly Subjects

Phase 1

Help build intelligence for Nxera Pharma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Active pipeline in high-value neurological indications including Alzheimer's disease and Dementia with Lewy Bodies, offering exposure to neurodegenerative disease R&D
Phase 3 program (Daridorexant for insomnia) represents near-term value inflection opportunity for clinical development professionals
Japanese pharma base provides access to Asia-Pacific market development and regulatory expertise, differentiating career track

Watch Out For

Zero active job postings signals minimal near-term hiring or potential organizational contraction despite public status
Pipeline heavily skewed toward early-stage Phase 1 studies (12 of 14 programs) with limited clinical validation and long probability-adjusted timelines to market
Lack of disclosed financials, revenue data, and R&D spend creates transparency gap for evaluating company stability and resource commitment

Generated by Claude from Nxera Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

HTL0014242

Healthy

PHASE_1

Clinical Trials (1)

NCT04462263Study to Investigate the Receptor Occupancy of HTL0014242 Using [18F] FPEB in Healthy Male Subjects

Phase 1

HTL0016878

Healthy Subjects

PHASE_1

Clinical Trials (1)

NCT04849286Measurement of HTL0016878 in Cerebrospinal Fluid

Phase 1